Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target

Benzinga · 1d ago
Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform and maintains $17 price target.